FDA Reviewing Prostate-Cancer Drugs for Heart, Diabetes Risk

[Guest guest]

The FDA is conducting a safety review of hormone-therapy drugs that are used to treat prostate cancer to see if the treatments increase the risk of heart attacks, strokes and diabetes. The drugs, which fall into a class of products known as gonadotropin-releasing hormone agonists, are sold under brand names that

include Abbott Laboratories' (ABT) Lupron, AstraZeneca PLC's (AZN, AZN.LN) Zoladex and Sanofi Aventis SA's (SNY, SAN.FR) Eligard. The products are designed to lower levels of male hormones, which can shrink

prostate tumors and slow the growth of prostate cancer....Click on below link for the full story: <http://online.wsj.com/article/BT-CO-20100503-710940.html?mod=WSJ_latestheadlines>